Table 2.
Recurrence outcomes by treatment group
| Number of events | 5-year probability (95% CI) | Hazard ratio (95% CI) | Log-rank p value* | |
|---|---|---|---|---|
| Vaginal recurrence (first recurrence) | ||||
| Chemoradiotherapy | 1 | 0·3% (0·0–2·1) | 0·99 (0·06–15·90) | 0·99 |
| Radiotherapy alone | 1 | 0·3% (0·0–2·1) | ·· | ·· |
| Pelvic recurrence (first recurrence) | ||||
| Chemoradiotherapy | 3 | 0·9% (0·3–2·8) | 0·75 (0·17–3·33) | 0·71 |
| Radiotherapy alone | 4 | 0·9% (0·3–2·8) | ·· | ·· |
| Distant metastases (first recurrence) | ||||
| Chemoradiotherapy | 78 | 21·4% (17·3–26·3) | 0·74 (0·55–0·99) | 0·047 |
| Radiotherapy alone | 98 | 29·1% (24·4–34·3) | ·· | ·· |
| Vaginal recurrence (total) | ||||
| Chemoradiotherapy | 8 | 2·1% (1·0–4·4) | 0·99 (0·37–2·65) | 0·99 |
| Radiotherapy alone | 8 | 2·1% (1·0–4·4) | ·· | ·· |
| Pelvic recurrence (total) | ||||
| Chemoradiotherapy | 20 | 5·5% (3·5–8·6) | 0·63 (0·36–1·11) | 0·11 |
| Radiotherapy alone | 31 | 8·5% (5·9–12·1) | ·· | ·· |
| Distant metastases (total) | ||||
| Chemoradiotherapy | 80 | 22·1% (17·9–27·0) | 0·75 (0·56–1·01) | 0·057 |
| Radiotherapy alone | 99 | 29·4% (24·7–34·6) | ·· | ·· |
*
Unadjusted for stratification factors.